user

Comparison of epirubicin and vinorelbine with cyclophosphamide, epirubicin, and fluorouracil as neoadjuvant chemotherapy for operable breast cancer

被引：0
|
作者：
Han, S. [1 ]
Kwak, K. [1 ]
Kim, J. [1 ]
Kim, J. [1 ]
Park, K. [1 ]
机构：
[1] Inje Univ, Sanggye Paik Hosp, Breast Canc Ctr, Seoul, South Korea
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [41] Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer
    Eisen, T
    Smith, IE
    Johnston, S
    Ellis, PA
    Prendiville, J
    Seymour, MT
    Walsh, G
    Ashley, S
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1350 - 1357
  • [42] Neoadjuvant chemotherapy of operable breast cancer with single-agent epirubicin: efficacy and predictive factors for response.
    Budd, G. T.
    Tubbs, R. R.
    Crowe, J.
    Weng, D.
    Moore, H.
    Cook, R.
    Swain, E.
    Prescott, N.
    Pettay, J.
    Tarr, S.
    Hicks, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S155 - S156
  • [43] Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil
    David Jamieson
    Jo Lee
    Nicola Cresti
    Rosanna Jackson
    Melanie Griffin
    Julieanne Sludden
    Mark Verrill
    Alan V. Boddy
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 667 - 674
  • [44] Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil
    Jamieson, David
    Lee, Jo
    Cresti, Nicola
    Jackson, Rosanna
    Griffin, Melanie
    Sludden, Julieanne
    Verrill, Mark
    Boddy, Alan V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 667 - 674
  • [45] Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: Is it cost-effective?
    Norum, J
    Holtmon, M
    ACTA ONCOLOGICA, 2005, 44 (07) : 735 - 741
  • [46] Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
    Levine, MN
    Bramwell, VH
    Pritchard, KI
    Norris, BD
    Shepherd, LE
    Abu-Zahra, H
    Findlay, B
    Warr, D
    Bowman, D
    Myles, J
    Arnold, A
    Vandenberg, T
    MacKenzie, R
    Robert, J
    Ottaway, J
    Burnell, M
    Williams, CK
    Tu, DS
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2651 - 2658
  • [47] Pharmacokinetic and pharmacodynamic analysis of cyclophosphamide, epirubicin and capecitabine vs 5-FU, epirubicin and cyclophosphamide as neoadjuvant therapy in breast cancer patients
    Milano, G.
    Deporte, R.
    Renee, N.
    Etienne-Grimaldi, M-C
    Berton, Rigaud D.
    Ferrero, J-M
    Dalenc, F.
    Piutti, M.
    Homokos, H.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S228 - S228
  • [48] Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial
    Futamura, Manabu
    Nagao, Yasuko
    Ishihara, Kazuhiro
    Takeuchi, Makoto
    Nakada, Takumi
    Kawaguchi, Yoshihiro
    Asano, Masayoshi
    Kumazawa, Iwao
    Shiroko, Takashi
    Morimitsu, Kasumi
    Mori, Ryutaro
    Nawa, Masahito
    Shimokawa, Toshio
    Yoshida, Kazuhiro
    BREAST CANCER, 2017, 24 (04) : 615 - 623
  • [49] Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial
    Manabu Futamura
    Yasuko Nagao
    Kazuhiro Ishihara
    Makoto Takeuchi
    Takumi Nakada
    Yoshihiro Kawaguchi
    Masayoshi Asano
    Iwao Kumazawa
    Takashi Shiroko
    Kasumi Morimitsu
    Ryutaro Mori
    Masahito Nawa
    Toshio Shimokawa
    Kazuhiro Yoshida
    Breast Cancer, 2017, 24 : 615 - 623
  • [50] Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)
    Chua, S
    Smith, IE
    A'Hern, RP
    Coombes, GA
    Hickish, TF
    Robinson, AC
    Laing, RW
    O'Brien, MER
    Ebbs, SR
    Hong, A
    Wardley, A
    Mughal, T
    Verrill, M
    Dubois, D
    Bliss, JM
    ANNALS OF ONCOLOGY, 2005, 16 (09) : 1435 - 1441
12345